AstraZeneca (LON:AZN) Stock Rating Reaffirmed by UBS Group

UBS Group reaffirmed their sell rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday, ThisIsMoney.Co.Uk reports.

Other equities research analysts also recently issued reports about the company. Goldman Sachs Group downgraded EXPERIAN PLC/ADR from a buy rating to a neutral rating in a research note on Wednesday, July 10th. Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the company a buy rating in a research note on Monday, July 15th. JPMorgan Chase & Co. downgraded Sogou from a neutral rating to an underweight rating and cut their price target for the company from $5.50 to $4.12 in a research note on Thursday, June 27th. Morgan Stanley boosted their price target on SYSCO from $69.00 to $72.00 and gave the company an equal weight rating in a research note on Tuesday, May 7th. Finally, Credit Suisse Group restated a sell rating and set a $6.50 price target on shares of Deutsche Bank in a research note on Monday, April 29th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of Hold and an average target price of GBX 6,502.94 ($84.97).

LON AZN opened at GBX 6,390 ($83.50) on Friday. AstraZeneca has a one year low of GBX 5,312 ($69.41) and a one year high of GBX 6,634 ($86.68). The stock has a 50-day simple moving average of GBX 6,299.76. The company has a market cap of $83.82 billion and a P/E ratio of 33.63. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57.

In related news, insider Philip A. J. Broadley acquired 520 shares of the stock in a transaction dated Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The shares were bought at an average cost of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Preferred Stock

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.